Clinical Trial Update: Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating gilteritinib in combination with venetoclax and azacitidine for FLT3-mutated acute myeloid leukemia patients ineligible for intens…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)
• Venclyxto (Venetoclax)
• Xospata (gilteritinib)

Snippet

Sponsor: Technische Universität Dresden | Conditions: AML - Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING